Scholarlink

<p>Inflammatory bowel disease (IBD) is featured by chronic intestinal inflammation, oxidative stress imbalance, impaired intestinal barrier and gut microbiota dysbiosis. Clinically, safe and efficient therapeutic regimens capable of realizing precise targeting, robust antioxidation and gut microbiota homeostasis restoration are still in urgent demand. Excessive intestinal accumulation of reactive oxygen species (ROS) acts as a core inducer of inflammatory exacerbation, mucosal injury and tissue fibrosis. Nevertheless, conventional small-molecule antioxidants are restricted by poor targeting capability and unsatisfactory in vivo stability, which greatly hampers their long-term ROS-scavenging performance. Recently, functional nanomaterials with multi-enzyme-mimicking properties have been developed to mimic endogenous antioxidant systems, facilitating in situ clearance of redundant ROS, suppression of proinflammatory cascades and maintenance of intestinal epithelial integrity. Combined with overexpressed receptors in the inflammatory microenvironment of IBD, can substantially enhance the oral stability, lesion accumulation and synergistic therapeutic efficiency of these biomaterials. This review systematically summarizes recent research advances in enzyme-mimetic targeted biomaterials, intelligent drug delivery carriers and engineered probiotics platforms against IBD. We particularly elaborate the developmental trend shifting from independent antioxidant treatment and targeted drug delivery toward synergistic therapy based on nanozyme and probiotics. Importantly, unstable nanozyme catalytic activity, unsatisfactory in vivo adaptability, uncontrollable probiotics colonization and bottlenecks of engineered probiotics for clinical transformation are comprehensively discussed. Eventually, future prospects of next-generation oral formulations with biodegradability, stimulus responsiveness and multi-target synergistic effects are proposed, providing theoretical references and innovative clues for developing safe, effective and precisely targeted therapeutic candidates for IBD.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Research Progress of Nanozyme-Functionalized Materials and Engineered Probiotics Synergistic System for Targeted Therapy of Inflammatory Bowel Disease

  • 期刊论文

  • 发表日期：

    2026年6月25日

查看全文
  • Xinyuan Li,
  • Chao Yan,
  • Lulu Zhao,
  • Huizhi Wang

摘要

Inflammatory bowel disease (IBD) is featured by chronic intestinal inflammation, oxidative stress imbalance, impaired intestinal barrier and gut microbiota dysbiosis. Clinically, safe and efficient therapeutic regimens capable of realizing precise targeting, robust antioxidation and gut microbiota homeostasis restoration are still in urgent demand. Excessive intestinal accumulation of reactive oxygen species (ROS) acts as a core inducer of inflammatory exacerbation, mucosal injury and tissue fibrosis. Nevertheless, conventional small-molecule antioxidants are restricted by poor targeting capability and unsatisfactory in vivo stability, which greatly hampers their long-term ROS-scavenging performance. Recently, functional nanomaterials with multi-enzyme-mimicking properties have been developed to mimic endogenous antioxidant systems, facilitating in situ clearance of redundant ROS, suppression of proinflammatory cascades and maintenance of intestinal epithelial integrity. Combined with overexpressed receptors in the inflammatory microenvironment of IBD, can substantially enhance the oral stability, lesion accumulation and synergistic therapeutic efficiency of these biomaterials. This review systematically summarizes recent research advances in enzyme-mimetic targeted biomaterials, intelligent drug delivery carriers and engineered probiotics platforms against IBD. We particularly elaborate the developmental trend shifting from independent antioxidant treatment and targeted drug delivery toward synergistic therapy based on nanozyme and probiotics. Importantly, unstable nanozyme catalytic activity, unsatisfactory in vivo adaptability, uncontrollable probiotics colonization and bottlenecks of engineered probiotics for clinical transformation are comprehensively discussed. Eventually, future prospects of next-generation oral formulations with biodegradability, stimulus responsiveness and multi-target synergistic effects are proposed, providing theoretical references and innovative clues for developing safe, effective and precisely targeted therapeutic candidates for IBD.